Indivior PLC

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. 11:35:14 2024-04-16 am EDT 5-day change 1st Jan Change
1,538 GBX -2.10% Intraday chart for Indivior PLC -5.35% +29.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Craig-Hallum Starts Indivior With Buy Rating, $37 Price Target MT
C4X Discovery seeks AIM delisting but half-year revenue skyrockets AN
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024 CI
Indivior CCO Richard Simkin sells GBP1 million in shares AN
UBS cuts abrdn price target but ups Darktrace's AN
Indivior Says Opvee Shows Drug Reverses Opioid-Induced Respiratory Depression Faster Than Naloxone MT
Indivior PLC Announces Publication Demonstrating that OPVEE® Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone CI
Indivior chief commercial officer sells GBP500,000 in shares AN
Oxford Nanopore Technologies top team buys shares AN
US Futures Flat, European Stocks Mixed After U.S. Stocks on Friday Started March in Fresh Record Territory DJ
Indivior says US court draws line on multi-district Suboxone case AN
Indivior Unit Obtains Final Settlement Approval Over Antitrust Multidistrict Litigation MT
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS... Our Logo
Health Care Up After Moderna Earnings -- Health Care Roundup DJ
Drugmaker Indivior consults on moving primary listing from London to US RE
Europe's STOXX 600 at all-time high as Nvidia boosts global tech shares RE
FTSE 100 Closes Up After Nvidia Results Lead to Global Rally DJ
European stocks boosted by ECB and Fed minutes AN
Indivior Q4 Adjusted Earnings, Revenue Increase; Sets 2024 Revenue Guidance -- Shares Climb Pre-Bell MT
Transcript : Indivior PLC, Q4 2023 Earnings Call, Feb 22, 2024
Stocks boosted as UK recession "already" over AN
Indivior plc Provides Revenue Guidance for the Year 2024 CI
FTSE 100 listless as losses in AstraZeneca offset earnings bump RE
Indivior swings to profit as eyes primary listing move to US AN
Indivior Initiates Shareholder Consultations Over Potential Transfer of Primary Listing MT
Chart Indivior PLC
More charts
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.57 USD
Average target price
31.37 USD
Spread / Average Target
+60.27%
Consensus
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. News Indivior PLC
  5. Indivior : Earnings Flash (INDV.L) INDIVIOR Reports H1 EPS $0.18